Feb 25, 2025
Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline
Dec 12, 2024
Ryvu Therapeutics provides an update on RVU120 Phase II program
Dec 05, 2024
Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)
Oct 29, 2024
Ryvu Therapeutics to Collaborate with nCage Therapeutics on the Development of a Next-Generation ADC Platform
Oct 23, 2024
Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium
Oct 09, 2024
Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium
Sep 23, 2024
Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit
Sep 19, 2024
Ryvu Therapeutics Announces Dosing of the First Patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Sep 12, 2024
Ryvu Therapeutics Reports 2024 Half-Year Financial Results and Provides Corporate Update
Jun 14, 2024
Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
May 15, 2024
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
May 14, 2024
Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
Apr 10, 2024
Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
Mar 13, 2024
Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update
Mar 06, 2024
Ryvu Therapeutics Announces Disbursement of First Tranche of EUR 8 Million Venture Debt from the European Investment Bank
Feb 14, 2024
Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS
Jan 31, 2024
Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory AML
Dec 01, 2020
Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting
Sep 16, 2020
First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia
Sep 15, 2020
Ryvu Therapeutics Reports 2020 Half-Year Financial Results